Autolus Therapeutics develops and makes T cell therapies for cancer and autoimmune diseases, and sells AUCATZYL for leukemia. It last closed at $1.09 on Nov 17, down 5.63% on the day.
AUTL · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 27% below its 20 day and 52% below its 50 day average. It is 52% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $1.07, and the nearest resistance the Pivot at $1.11.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.5%/day
Key levels
$2.5852 week high+136.7%
$1.77100 day average+62.4%
$1.6650 day average+52.3%
$1.66200 day average+52.3%
$1.3920 day average+27.5%
$1.38Swing high (Nov 10)+26.6%
$1.13Pivot R1+3.7%
$1.11Pivot+1.8%
$1.09Last close
$1.0752 week low−1.8%
$1.06Pivot S1−2.8%
Indicators
RSI (14)
22.17
Oversold below 30
Oversold
MACD
-0.15
Below its signal line
Bearish
Stochastic
9.2
Near the bottom of its range
Oversold
ADX (14)
45.1
Strong downtrend
Williams %R
-96.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-125.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.0%
Change over 10 sessions
Bearish
ATR (14)
$0.10
Typical daily range, 9.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.8%/day
Key levels
$2.5852 week high+136.7%
$1.77100 day average+62.4%
$1.6650 day average+52.3%
$1.66200 day average+52.3%
$1.3920 day average+27.5%
$1.38Swing high (Nov 10)+26.6%
$1.13Pivot R1+3.7%
$1.11Pivot+1.8%
$1.09Last close
$1.0752 week low−1.8%
$1.06Pivot S1−2.8%
Indicators
RSI (14)
33.01
Weak, oversold below 30
Neutral
MACD
-0.11
Below its signal line
Bearish
Stochastic
2.9
Near the bottom of its range
Oversold
ADX (14)
17.0
No clear trend
Williams %R
-98.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-141.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−42.0%
Change over 10 sessions
Bearish
ATR (14)
$0.24
Typical daily range, 21.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AUTL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AUTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow AUTL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AUTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AUTL is in one of them and how their past AUTL trades turned out.
Autolus Therapeutics is a biopharmaceutical company based in London, United Kingdom. It develops and manufactures cell therapies that reprogram a patient's own T cells so they can recognize and attack target cells. Its main product, AUCATZYL, is approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States and the United Kingdom. The company is also testing its therapy in other cancers and in autoimmune diseases such as lupus and multiple sclerosis.